Assertion Failure: 
Message: Gene summary, Query: BRCA1 Oncogenic Mutations

Expected:
1 (Ovarian Cancer): Olaparib; 1 (Ovary/Fallopian Tube): Olaparib; 1 (Peritoneal Serous Carcinoma): Olaparib; 1 (Prostate Cancer, NOS): Olaparib; 1 (Prostate Cancer): Olaparib; 1 (Ovarian Cancer): Olaparib+Bevacizumab; 1 (Ovary/Fallopian Tube): Olaparib+Bevacizumab; 1 (Peritoneal Serous Carcinoma): Olaparib+Bevacizumab; 1 (Prostate Cancer, NOS): Rucaparib; 1 (Prostate Cancer): Rucaparib; 1 (Prostate Cancer, NOS): Olaparib+Abiraterone+Prednisone; 1 (Prostate Cancer): Olaparib+Abiraterone+Prednisone; 1 (Ovarian Cancer): Rucaparib; 1 (Ovary/Fallopian Tube): Rucaparib; 1 (Peritoneal Serous Carcinoma): Rucaparib; 1 (Ovarian Cancer): Niraparib; 1 (Ovary/Fallopian Tube): Niraparib; 1 (Peritoneal Serous Carcinoma): Niraparib; 1 (Prostate Cancer, NOS): Talazoparib+Enzalutamide; 1 (Prostate Cancer): Talazoparib+Enzalutamide; 1 (Prostate Cancer, NOS): Niraparib+Abiraterone Acetate+Prednisone; 1 (Prostate Cancer): Niraparib+Abiraterone Acetate+Prednisone; 2 (Pancreatic Adenocarcinoma): Rucaparib; 2 (Acinar Cell Carcinoma of the Pancreas): Rucaparib; 3A (Pancreatic Adenocarcinoma): Olaparib; 3A (Acinar Cell Carcinoma of the Pancreas): Olaparib; 3A (Breast Cancer): Talazoparib; 3A (Breast Cancer): Olaparib;

Actual:
1 (Ovary/Fallopian Tube): Olaparib; 1 (Peritoneal Serous Carcinoma): Olaparib; 1 (Ovarian Cancer): Olaparib; 1 (Prostate Cancer): Olaparib; 1 (Ovary/Fallopian Tube): Olaparib+Bevacizumab; 1 (Peritoneal Serous Carcinoma): Olaparib+Bevacizumab; 1 (Ovarian Cancer): Olaparib+Bevacizumab; 1 (Prostate Cancer): Rucaparib; 1 (Prostate Cancer): Olaparib+Abiraterone+Prednisone; 1 (Ovary/Fallopian Tube): Rucaparib; 1 (Peritoneal Serous Carcinoma): Rucaparib; 1 (Ovarian Cancer): Rucaparib; 1 (Ovary/Fallopian Tube): Niraparib; 1 (Peritoneal Serous Carcinoma): Niraparib; 1 (Ovarian Cancer): Niraparib; 1 (Prostate Cancer): Talazoparib+Enzalutamide; 1 (Prostate Cancer): Niraparib+Abiraterone Acetate+Prednisone; 2 (Pancreatic Adenocarcinoma): Rucaparib; 2 (Acinar Cell Carcinoma of the Pancreas): Rucaparib; 3A (Pancreatic Adenocarcinoma): Olaparib; 3A (Acinar Cell Carcinoma of the Pancreas): Olaparib; 3A (Breast Cancer): Talazoparib; 3A (Breast Cancer): Olaparib;

Full Error:
Gene summary, Query: BRCA1 Oncogenic Mutations expected:<1 (Ovar[ian Cancer): Olaparib; 1 (Ovary/Fallopian Tube): Olaparib; 1 (Peritoneal Serous Carcinoma): Olaparib; 1 (Prostate Cancer, NOS): Olaparib; 1 (Prostate Cancer): Olaparib; 1 (Ovarian Cancer): Olaparib+Bevacizumab; 1 (Ovary/Fallopian Tube): Olaparib+Bevacizumab; 1 (Peritoneal Serous Carcinoma): Olaparib+Bevacizumab; 1 (Prostate Cancer, NOS): Rucaparib; 1 (Prostate Cancer): Rucaparib; 1 (Prostate Cancer, NOS): Olaparib+Abiraterone+Prednisone; 1 (Prostate Cancer): Olaparib+Abiraterone+Prednisone; 1 (Ovarian Cancer): Rucaparib; 1 (Ovary/Fallopian Tube): Rucaparib; 1 (Peritoneal Serous Carcinoma): Rucaparib; 1 (Ovarian Cancer): Niraparib; 1 (Ovary/Fallopian Tube): Niraparib; 1 (Peritoneal Serous Carcinoma): Niraparib; 1 (Prostate Cancer, NOS): Talazoparib+Enzalutamide; 1 (Prostate Cancer): Talazoparib+Enzalutamide; 1 (Prostate Cancer, NOS): Niraparib+Abiraterone Acetate+Prednison]e; 1 (Prostate Cance...> but was:<1 (Ovar[y/Fallopian Tube): Olaparib; 1 (Peritoneal Serous Carcinoma): Olaparib; 1 (Ovarian Cancer): Olaparib; 1 (Prostate Cancer): Olaparib; 1 (Ovary/Fallopian Tube): Olaparib+Bevacizumab; 1 (Peritoneal Serous Carcinoma): Olaparib+Bevacizumab; 1 (Ovarian Cancer): Olaparib+Bevacizumab; 1 (Prostate Cancer): Rucaparib; 1 (Prostate Cancer): Olaparib+Abiraterone+Prednisone; 1 (Ovary/Fallopian Tube): Rucaparib; 1 (Peritoneal Serous Carcinoma): Rucaparib; 1 (Ovarian Cancer): Rucaparib; 1 (Ovary/Fallopian Tube): Niraparib; 1 (Peritoneal Serous Carcinoma): Niraparib; 1 (Ovarian Cancer): Niraparib; 1 (Prostate Cancer): Talazoparib+Enzalutamid]e; 1 (Prostate Cance...>


